Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905060 · ClinicalTrials.gov registry record · Phase 2
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00905060 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 70 participants.
The verdict
NCT00905060, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well HSPPC-96 (vitespen) and temozolomide work in treating patients with newly diagnosed glioblastoma multiforme. Vaccines made from a person's tumor cells and heat shock protein peptide may help the body to build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving HSPPC-96 (vitespen) together with temozolomide may kill more tumor cells.
Interventions
- DRUG Temozolomide
- BIOLOGICAL HSPPC-96
- PROCEDURE Standard Surgical Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-06-29 |
| Est. Completion | 2014-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905060
The ClinicalTrials.gov registry entry for NCT00905060 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT00905060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905060 about?
NCT00905060 is a clinical study titled "HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM". This phase II trial studies the side effects and how well HSPPC-96 (vitespen) and temozolomide work in treating patients with newly diagnosed glioblastoma multiforme. Vaccines made from a person's tumor cells and heat shock protein peptide may help the body to build an effective immune response to k...
What is the current status of trial NCT00905060?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-06-29. Estimated completion is 2014-06-03.
What interventions are being tested in trial NCT00905060?
The interventions under investigation include: Temozolomide (DRUG), HSPPC-96 (BIOLOGICAL), Standard Surgical Resection (PROCEDURE).
Who is sponsoring clinical trial NCT00905060?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.